Monoprost (Latanoprost)

Latanoprost is a prostaglandin F‑type receptor agonist. By binding to FP receptors in the ciliary body, it remodels extracellular matrix and increases uveoscleral outflow of aqueous humor, which reduces intraocular pressure.

The dosing regimen is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily in the evening, but the exact schedule should follow the prescriber’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the Monoprost product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost belongs to the prostaglandin analog class, which generally provides strong, once‑daily pressure reduction with a favorable safety profile. Compared with other agents such as travoprost or bimatoprost, latanoprost has similar efficacy but may differ in side‑effect patterns, such as iris pigmentation changes.

Monoprost eye drops should be stored at room temperature, below 25 °C, in the original container. Keep the bottle tightly closed, protect it from light and moisture, and discard any product that appears discolored or cloudy.

Wash your hands, tilt the head back, and gently pull down the lower eyelid to create a small pocket. Instill one drop into the conjunctival sac without touching the tip to the eye or lashes. Close the eye gently for a few seconds and avoid blinking excessively.

Serious adverse events, although rare, include uveitis, macular edema, severe allergic reactions, and sudden loss of vision. Patients should seek immediate medical attention if they experience eye pain, significant visual changes, or signs of inflammation.

Monoprost is contraindicated in individuals with known hypersensitivity to latanoprost or any component of the formulation, and it should be avoided in eyes with active infection, inflammation, or severe ocular surface disease.